Shots:

• Pfizer has identified the preferred danuglipron’s QD modified release formulation on the basis of PK trial that is underway; anticipates dose optimization trial to assess various dosing levels for registrational studies in H2’24
• The P-I study is assessing PK & safety of immediate & modified release danuglipron (oral) formulations among healthy subjects (age: ≥18yrs), the results of which did not show liver enzyme elevations in >1400 subjects with a consistent safety profile & PK supporting QD dosing
• Danuglipron (PF-06882961) is a GLP-1 receptor agonist, developed in-house by Pfizer, aims at maintaining healthy blood sugar levels by increasing insulin level with other results such as slowing the digestion linked with weight loss

Ref: Pfizer | Image: Pfizer

Related News:- Evotec Partners with Pfizer for Drug Discovery Advancement Across France

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com